"Smoldering systemic mastocytosis". Successful therapy with cladribine;"Smouldering systemic mastocytosis". Erfolgreiche therapie mit cladribin

Hautarzt

Volumn 55, Issue 7, 2004, Pages 658-662

  Schleyer, V ^a   Meyer, S ^a   Landthaler, M ^a   Szeimies, R M ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Cladribine; Glucocorticosteroids; Interferon ; Mastocytosis; Urticaria pigmentosa

Indexed keywords

ALPHA INTERFERON; ANTIHISTAMINIC AGENT; CLADRIBINE; CYTOSTATIC AGENT; GLUCOCORTICOID; TRYPTASE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; MAST CELL LEUKEMIA; PHYSICAL EXAMINATION; PUVA; SMOLDERING SYSTEMIC MASTOCYTOSIS; SYSTEMIC MASTOCYTOSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOPSY; CLADRIBINE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; SKIN; TREATMENT OUTCOME;

EID: 3242676908     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Escribano L, Orfao A, Diaz Agustin B et al. (1998) Human bone marrow mast cells from indolent systemic mast cell disease constitutively express increased amounts of the CD63 protein on their surface. Cytometry 34:223-228
2. Escribano L, Perez de Oteyza J, Nunez R, Orfano A (2002) Cladribine induces immunophenotypical changes in bone marrow mast cells from mastocytosis: report of a case of mastocytosis associated with a lymphoplasmocytic lymphoma. Leuk Res 26:1043-1046
3. Godt O, Proksch E, Streit V, Christophers D (1997) Short-and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. Dermatology 195:35-39
4. Hartmann K, Bruns S, Henz B (2001) Mastocytosis: review of clinical and experimental aspects. J Invest Dermatol Symp Proc 6:143-147
5. Hoffman MA, Janson D, Rose E, Rai KR (1997) Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. J Clin Oncol 15:1138-1142
6. Johnson SA (2001) Nucleoside analogues in the treatment of haematological malignancies. Expert Opin Pharmacother 2:929-943
7. Kolde G, Frosch PJ, Czarnetzki BM (1984) Response of cutaneous mast cells to PUVA in patients with urticaria pigmentosa: histomorphometric, ultrastructural and biochemical investigations. J Invest Dermatol 83:175-178
8. Longley BJ, Metcalfe DD (2000) A proposed classification of mastocytosis incorporating molecular genetics. Hematol Oncol Clin North Am 14:697-701
9. Longley BJ, Metcalfe DD, Tharp M (1999) Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 96:1609-1614
10. Marone G, Spadaro G, Granata F, Triggiani M (2001) Treatment of mastocytosis: pharmacologic basis and current concepts. Leuk Res 25:583-594
11. Metcalfe DD (1991) Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 96:2S-4S
12. Sperr WR, Horny HP, Lechner K, Valent P (2000) Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leukemia Lymphoma 37:473-486
13. Tefferi A, Chin-Yang L, Butterfield JH, Hoagland HC (2001) Treatment of systemic mast cell disease with cladribine. N Eng J Med 344:307-309
14. Topar G, Staudacher C, Geisen F (1998) Urticaria pigmentosa: a clinical, hematopathologic, and serologic study of 30 adults. Am J Clin Pathol 109:279-285
15. Tortorella C, Rovaris M, Filippi M (2001) Cladribine: Ortho Biotech Inc. Curr Opin Invest Drugs 2:1751-1756
16. Valent P, Homy HP, Escribano L et al. (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 35:603-625
17. Wolff K (2002) Treatment of cutaneous mastocytosis. Int Arch Allergy Immunol 127:156-159
18. Worobec AS (2000) Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 14:659-687
19. Worobec A, Metcalfe DD (2002) Mastocytosis: current treatment concepts. Int Arch Allergy Immunol 127:153-155